KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Equity Ratio (2016 - 2025)

Gilead Sciences (GILD) has disclosed Equity Ratio for 16 consecutive years, with 0.33 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Equity Ratio fell 10.91% year-over-year to 0.33, compared with a TTM value of 0.33 through Dec 2024, down 10.91%, and an annual FY2024 reading of 0.33, down 10.91% over the prior year.
  • Equity Ratio was 0.33 for Q4 2024 at Gilead Sciences, down from 0.34 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.37 in Q1 2020 and bottomed at 0.27 in Q4 2020.
  • Average Equity Ratio over 5 years is 0.32, with a median of 0.33 recorded in 2024.
  • The sharpest move saw Equity Ratio decreased 27.53% in 2020, then increased 16.38% in 2021.
  • Year by year, Equity Ratio stood at 0.27 in 2020, then rose by 16.38% to 0.31 in 2021, then rose by 8.31% to 0.34 in 2022, then increased by 9.07% to 0.37 in 2023, then dropped by 10.91% to 0.33 in 2024.
  • Business Quant data shows Equity Ratio for GILD at 0.33 in Q4 2024, 0.34 in Q2 2024, and 0.31 in Q1 2024.